NasdaqGS - Nasdaq Real Time Price USD

Editas Medicine, Inc. (EDIT)

1.5600

0.0000

(0.00%)

At close: April 23 at 4:00:01 PM EDT

1.5792

+0.02

+(1.23%)

Pre-Market: 9:13:35 AM EDT

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Key Insights Given the large stake in the stock by institutions, Editas Medicine's stock price might be vulnerable to...

Simply Wall St. yesterday

EDIT
0.00%
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 19 days ago

EDIT
0.00%
AstraZeneca deepens China investment; Editas loses CFO to Dyne

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

BioPharma Dive last month

AZN

EDIT
0.00%
PFE
Editas Medicine Announces Chief Financial Officer Transition

Amy Parsion Senior Vice President of Finance Amy Parison Appointed CFO Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy

GlobeNewswire last month

EDIT
0.00%
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. last month

EDIT
0.00%
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

Zacks last month

EDIT
0.00%
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -41.03% and 19.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

EDIT
0.00%
Editas: Q4 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Editas Medicine Inc. EDIT) on Wednesday reported a loss of $45.4 million in its fourth quarter.

Associated Press Finance last month

EDIT
0.00%
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pio

GlobeNewswire last month

EDIT
0.00%
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the fo

GlobeNewswire last month

EDIT
0.00%
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

PTCT

EDIT
0.00%
Editas Medicine Outlines 2025 Strategic Priorities and Milestones

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, aiming to advance its gene editing technologies targeting hematopoietic stem cells and liver cells. The company plans to declare two in vivo development candidates and expand its therapeutic possibilities, positioning itself as a leader in the in vivo gene editing field with a strong financial runway in

TipRanks 3 months ago

EDIT
0.00%
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks 3 months ago

CAH

EDIT
0.00%
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized mice Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo da

GlobeNewswire 3 months ago

EDIT
0.00%
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year.

Zacks 3 months ago

ADAG

EDIT
0.00%
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com. An arc

GlobeNewswire 3 months ago

EDIT
0.00%
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging […]

Insider Monkey 3 months ago

EDIT
0.00%
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

Zacks 4 months ago

EDIT
0.00%
CSTL
Editas Medicine price target lowered to $8 from $10 at Baird

Baird lowered the firm’s price target on Editas Medicine (EDIT) to $8 from $10 and keeps an Outperform rating on the shares. The firm said they expect the shares could move higher as the in vivo programs move towards the clinic and clinical data nears, though it could be a number of quarters before momentum begins to build. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on EDIT: Edi

TipRanks 4 months ago

EDIT
0.00%
Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Investing.com -- Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target citing a lack of near-term catalysts, the latter hacked it to $3 from $11.

Investing.com 4 months ago

EDIT
0.00%
TFC

Performance Overview

Return	EDIT	S&P 500 (^GSPC)
YTD	+22.83%	-8.60%
1-Year	-71.43%	+6.02%
3-Year	-89.31%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

AstraZeneca deepens China investment; Editas loses CFO to Dyne

Editas Medicine Announces Chief Financial Officer Transition

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

Editas: Q4 Earnings Snapshot

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas Medicine price target lowered to $8 from $10 at Baird

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Performance Overview